Group Pharmaceuticals Latest Annual Report, Balance Sheet and Financials

Group Pharmaceuticals Limited Standalone Balance Sheet (Rs in Lakhs)

Particulars	31-03-2024	31-03-2023
Shareholders’ Funds
Share Capital	253.679	253.68
Reserves and Surplus	5,523.84	4,578.86
Non-Current Liabilities
Deferred Tax Liabilities (Net)	3.23	0
Long-Term Provisions	73.09	180.19
Trade Payables	726.25	577.92
Other Current Liabilities	640.11	512.51
Short-Term Provisions	48.5	69.62
Total Equity and Liabilities	7268.699	6172.78
Non-Current Assets
Tangible Assets	1,419.21	1,541.63
Intangible Assets	5.23	6.11
Non-Current Investments	298	248
Deferred Tax Assets (Net)	0	23.97
Long-Term Loans and Advances	63.7	70.37
Current Assets
Inventories	840.2	1128.48
Trade Receivables	2860.26	2234.21
Cash and Bank Balances	1371.02	565.78
Short-Term Loans and Advances	398.69	350.98
Other Current Assets	12.39	3.25
Total Assets	7268.7	6172.78

 Group Pharmaceuticals Limited Standalone Profit & Loss Statement (Rs in Lakhs)

Particulars	31-03-2024	31-03-2023
Revenue
Revenue from sale of products	15072.16	13187.08
Other operating revenues	94.18	110.13
Other income	152.71	96.54
Total Revenue	15319.68	13393.75
Expenses
Cost of materials consumed	5288.83	4700.09
Purchases of stock-in-trade	1036.18	1280.57
Changes in inventories of finished goods, work-in-progress and stock-in-trade	84.74	190.27
Employee benefit Expenses	4016.07	3670.4
Finance Costs	25.63	38.81
Depreciation Expense	188.78	202.53
CSR Expenditure	11.76	10.4
Other Expenses	3316.12	2670.63
Total Expenses	13968.11	12763.7
Profit Before Tax	1351.57	630.05
Current Tax	328.64	183.3
Deffered Tax	27.21	-4.49
Total profit (loss) for period	995.72	451.24
Earnings per equity share
Basic earning per equity share	39.25	17.79
Diluted earnings per equity share	39.25	17.79

 Group Pharmaceuticals Limited Standalone Cash Flow Statement (Rs in Lakhs)

Particulars	31-03-2024	31-03-2023
Cash flows from used in operating activities
Profit before extraordinary items and tax	1351.57	630.05
Adjustments for finance costs	25.63	38.81
Adjustments for depreciation and amortisation expense	188.78	202.53
Other adjustments to reconcile profit (loss)	6.71	-1.51
Other adjustments for non-cash items	1.83	0
Total adjustments to profit (loss)	222.95	239.83
Adjustments for working capital
Adjustments for decrease (increase) in inventories	288.87	253.5
Adjustments for decrease (increase) in trade receivables	-627.88	-30.67
Adjustments for decrease (increase) in other current assets	-69.08	32.9
Adjustments for increase (decrease) in trade payables	148.32	-222.3
Adjustments for increase (decrease) in other current liabilities	127.6	65.81
Adjustments for provisions	-128.22	-7.77
Total adjustments for working capital	-260.99	91.47
Total adjustments for reconcile profit (loss)	-38.04	331.3
Net cash flows from (used in) operations	1313.53	961.35
Income taxes paid (refund)	309.71	204.93
Net cash flows from (used in) operating activities before extraordinary items	1003.82	756.42
Net cash flows from (used in) operating activities	1003.82	756.42
Cash flows from used in investing activities
Other cash receipts from sales of equity or debt instruments of other entities	-50	-472.44
Purchase of tangible assets	72.21	194.87
Other inflows (outflows) of cash	-740.62	429.01
Net cash flows from (used in) investing activities before extraordinary item	-862.83	-238.3
Net cash flows from (used in) investing activities	-862.83	-238.3
Cash flows from used in financing activities
Proceeds from borrowings	0	-185.02
Repayments of borrowings	0	28
Dividends paid	50.74	50.74
Interest paid	25.63	38.81
Net cash flows from (used in) financing activities before extraordinary items	-76.37	-302.57
Net cash flows from (used in) financing activities	-76.37	-302.57
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	64.62	215.55
Net increase (decrease) in cash and cash equivalents	64.62	215.55
Cash and cash equivalents cash flow statement at end of period	386.73	322.11

 Here is a summary of the Cash Flow Statement for the years 2024 and 2023:

Operating Activities

The company reported a strong net cash inflow of ₹1,003.82 lakhs from operating activities. This was primarily driven by a significant increase in profit before tax, along with positive adjustments for non-cash expenses such as depreciation and finance costs. However, the working capital changes had a moderately adverse impact, mainly due to a substantial rise in trade receivables, partially offset by an increase in trade payables and a reduction in inventories.

 Investing Activities

Investing activities led to a net cash outflow of ₹862.83 lakhs. The outflow was primarily due to substantial other cash outflows and the purchase of tangible assets. Although there was a minor reduction in outflows compared to the previous year, the continued investments indicate ongoing capital expenditures or other long-term uses of funds.

 Financing Activities

Financing activities resulted in a net cash outflow of ₹76.37 lakhs. This was due to dividend payments and interest expenses, with no new borrowings raised during the year. The absence of financing inflows suggests that the company relied on internal accruals to fund its operations and investments.

 Net Change in Cash and Cash Equivalents

Overall, the company recorded a net increase in cash and cash equivalents of ₹64.62 lakhs during the year. The closing balance rose to ₹386.73 lakhs as on 31st March 2024, compared to ₹322.11 lakhs in the previous year, reflecting a positive cash position mainly supported by strong operational performance.

Financial Ratios of Group Pharmaceuticals Limited

Particulars	31-Mar-2024	31-Mar-2023
Current Ratio	3.87	3.69
Debt - Equity Ratio	-	-
Debt Service Coverage Ratio	124.29	15.73
Return on Equity (ROE)	18.77%	9.74%
Trade Receivables Turnover Ratio	5.95	5.96
Trade Payables Turnover Ratio	9.39	8.59
Net Capital Turnover Ratio	3.73	4.58
Net Profit Ratio	6.50%	3.37%
Return on Capital Employed (ROCE)	23.30%	13.10%
Return on Investment (ROI)	13.99%	1.03%

 Here is a summary of the financial and operational metrics for Group Pharmaceuticals Limited for the years 2024 and 2023:

 Current Ratio

The current ratio improved slightly to 3.87 in FY 2023–24 from 3.69 in the previous year, indicating a strong liquidity position. The company has ample current assets to meet its short-term obligations.

 Debt-Equity Ratio

The debt-equity ratio is marked as not applicable for both years, suggesting that the company either has no borrowings or an insignificant debt component, reflecting a conservative capital structure.

 Debt Service Coverage Ratio (DSCR)

DSCR surged from 15.73 to 124.29, reflecting a massive improvement in the company’s ability to service debt from operational earnings. This indicates robust cash generation and strong financial health.

 Return on Equity (ROE)

ROE increased sharply to 18.77% from 9.74%, signifying that the company has become more efficient in generating profits for its shareholders.

 Trade Receivables Turnover Ratio

The ratio remained stable at 5.95 compared to 5.96 last year, showing consistent efficiency in the collection of receivables and effective credit control.

 Trade Payables Turnover Ratio

The trade payables turnover ratio improved from 8.59 to 9.39, indicating the company is settling its payables faster, which could either reflect better cash flow management or a shift in supplier terms.

 Net Capital Turnover Ratio

This ratio declined from 4.58 to 3.73, indicating a lower efficiency in using working capital to drive revenues. It may reflect higher working capital requirements or slower turnover of current assets.

 Net Profit Ratio

The net profit ratio rose significantly to 6.50% from 3.37%, showing improved profitability and cost control. The company has managed to convert a higher portion of its revenue into net profit.

 Return on Capital Employed (ROCE)

ROCE increased to 23.30% from 13.10%, demonstrating more efficient utilization of capital employed in generating operating profits. This is a key indicator of improved overall business performance.

 Return on Investment (ROI)

ROI witnessed a dramatic increase from 1.03% to 13.99%, suggesting significantly better returns from investments during the year, either from better asset performance or more strategic investment decisions.